ICMR to Lead First-In-Human Clinical Trials for Blood Cancers, Zika, and Flu
Saturday, 14 September 2024, 03:20
ICMR's Initiative for Blood Cancers, Zika, and Flu Trials
In a significant development, the Indian Council of Medical Research (ICMR) has announced collaborations to spearhead first-in-human clinical trials targeting blood cancers, Zika, and seasonal flu vaccines.
Strengthening India's Clinical Research Ecosystem
- ICMR partners with industry and academic sectors.
- Formalized agreements for multiple promising molecules.
- Focus on affordable and accessible healthcare solutions.
Specific Collaborations
- Collaboration with Aurigene Oncology for multiple myeloma treatment.
- Partnership with Indian Immunologicals for a Zika vaccine.
- Mynvax Private engaged for the seasonal influenza vaccine trial.
- ImmunoACT for CAR-T cell therapy in chronic lymphocytic leukemia.
The initiative is a key milestone to make India a global hub for healthcare innovations. Union Health Minister J P Nadda emphasized the importance of these advancements for the future of medical treatments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.